HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Very long-term outcomes after a single catheter ablation procedure for the treatment of atrial fibrillation-the protective role of antiarrhythmic drug therapy.

AbstractBACKGROUND:
Pulmonary vein isolation (PVI) is the cornerstone of AF ablation, but its long-term clinical outcomes, predictors of relapse, and optimal pharmacological treatment remain controversial.
OBJECTIVE:
The objectives of this paper were to (1) assess very long-term AF recurrence, (2) identify predictors of relapse, and (3) evaluate the impact of continued antiarrhythmic drug (AAD) treatment after ablation.
METHODS:
Multicenter observational registry including all consecutive patients with drug-resistant AF who underwent a first PVI between 2006 and 2008 (n = 253 (age 55 years (IQR 48-63)), 80% males, 64% with paroxysmal AF. Endpoint was AF/AT/AFL relapse after a 3-month blanking period. Predictors and protective factors of AF relapse were assessed with multivariate Cox regression.
RESULTS:
A total of 144 patients (57%) relapsed over a median 5-year (IQR 2-9) follow-up-annual relapse rate of 10%/year. Female sex (aHR 1.526, 95% CI 1.037-2.246, P = 0.032), non-paroxysmal AF (aHR 1.410, 95% CI 1.000-1.987, P = 0.050), and LA volume/BSA (aHR 1.012, 95% CI 1.003-1.021, P = 0.008) were identified as independent predictors of relapse. A total of 139 patients (55%) continued AAD (55% on amiodarone) after blanking period. One-year overall PVI success rate of patients under AAD was 86 vs 76% with no AAD (P < 0.001)-annual relapse rates were 8%/year vs 14%/year (P < 0.001), respectively. AAD was associated with a long-term reduction in AF relapse (aHR 0.673, 95% CI 0.509-0.904 P = 0.004).
CONCLUSION:
Half the patients remained free from AF 5 years after a single procedure. Female sex, non-paroxysmal AF, and LA volume/BSA independently predicted recurrence, whereas continuing AAD after the 3-month blanking period reduced relapse. In a multicenter registry of AF patients undergoing a first PVI, 57% relapsed over a median 5-year follow-up. Female sex, non-paroxysmal AF and LA volume/BSA were identified as independent predictors of relapse. Maintaining AAD therapy after the blanking period was associated with a long-term reduction in AF relapse.
AuthorsJoão Mesquita, Diogo Cavaco, António Miguel Ferreira, Francisco Moscoso Costa, Pedro Carmo, Francisco Morgado, Miguel Mendes, Pedro Adragão
JournalJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing (J Interv Card Electrophysiol) Vol. 52 Issue 1 Pg. 39-45 (Jun 2018) ISSN: 1572-8595 [Electronic] Netherlands
PMID29511973 (Publication Type: Journal Article, Multicenter Study, Observational Study)
Chemical References
  • Anti-Arrhythmia Agents
Topics
  • Aged
  • Anti-Arrhythmia Agents (therapeutic use)
  • Atrial Fibrillation (diagnostic imaging, drug therapy, surgery)
  • Catheter Ablation (adverse effects, methods)
  • Combined Modality Therapy
  • Electrocardiography (methods)
  • Female
  • Follow-Up Studies
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Proportional Hazards Models
  • Pulmonary Veins (surgery)
  • Recurrence
  • Registries
  • Risk Assessment
  • Severity of Illness Index
  • Time
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: